BioRestorative Therapies, Inc. Cash Flow Statement
BRTX|14 years of annual SEC 10-K data (FY2012-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 14 fiscal years. All figures from audited SEC 10-K filings.
BioRestorative Therapies, Inc. used $11M in operating cash flow and negative free cash flow of $11M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -47.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$14.2M | -$10.4M | -$10.4M | -$18.5M | -$44.3M | -$14.6M | -$12.5M | -$9.4M | -$8.6M | -$7.9M | -$5.6M | -$5.8M | $0 | -$1.2M |
| Depreciation & Amortization | $210.0K | $165.7K | $165.7K | $120.5K | $89.1K | $217.4K | $240.4K | $259.3K | $258.4K | $213.8K | $96.7K | $104.8K | $90.4K | $90.4K |
| Operating Cash Flow | -$10.8M | -$6.4M | -$6.4M | -$5.9M | -$3.3M | -$6.9M | -$5.1M | -$3.9M | -$5.0M | -$3.1M | -$3.2M | -$2.7M | -$3.2M | -$2.8M |
| Capital Expenditures | $116.1K | $171.0K | $171.0K | $265.2K | $30.7K | $35.6K | $12.9K | $3.6K | $188.8K | $408.1K | $168.4K | $11.2K | $2.5K | $65.0K |
| Free Cash Flow | -$10.9M | -$6.6M | -$6.6M | -$6.2M | -$3.4M | -$7.0M | -$5.1M | -$3.9M | -$5.2M | -$3.5M | -$3.4M | -$2.7M | -$3.2M | -$2.9M |
| Share Buybacks | $0 | - | - | - | - | - | - | - | - | - | - | - | $0 | $4.0K |
| FCF Margin | -3031.7% | -4527.6% | -4527.6% | -5157.2% | -7305.6% | -5349.5% | -4610.4% | -4762.3% | -14279.8% | -561.3% | -816.4% | -159736.0% | -20441.6% | - |